Use of the Glialia Supplement in the Treatment of Persistent Perceptual Postural Imbalance A Triple-Blind, Randomized, Placebo-Controlled Pilot Clinical Trial

What this Trial Is About

Researchers are evaluating the use of the Glialia supplement in people diagnosed with Persistent Perceptual Postural Dizziness (PPPD). This pilot study involves 30 participants, including 20 PPPD patients who may or may not have had a previous COVID-19 infection, and 10 control participants who have recovered from COVID-19. The main goal is to compare neuroinflammation levels between PPPD patients and controls and to see if Glialia reduces neuroinflammation more than a placebo. The trial is triple-blind, meaning neither participants nor researchers know who receives which treatment. Participants are randomly assigned to one of three groups: PPPD patients receiving Glialia, PPPD patients receiving a placebo that looks identical to Glialia, and control participants who have recovered from COVID-19 and receive Glialia. All participants take two soluble sachets daily for 60 days. The Glialia supplement contains 700 mg of Palmitoylethanolamide (umPEA) with supportive ingredients. The placebo group receives a matching treatment without active ingredients. During the study, participants will be assessed at the start and after 60 days for neuroinflammation levels. Additional evaluations include gait quality, dizziness impact, brain fog, and personality traits. Researchers will monitor mental clarity, quality of life, balance, and neuroinflammation changes. The study provides all treatments at no cost and includes safety and outcome monitoring throughout the 60-day treatment period.

Using Glialia for Treating Persistent Perceptual Postural Dizziness